Other languages Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
3.2 ^USD	+0.63%		+7.02%	-37.86%

04-15	Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	CI
04-15	Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	04-15
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	11-20
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	11-16
Sector Update: Health Care	11-16
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	11-16
Reviva Pharmaceuticals to Seek Acquisitions	11-16
Reviva Pharmaceuticals Holdings Q3 Loss Widens	11-14
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Sector Update: Health Care Stocks Gain Late Afternoon	30/10/23
Sector Update: Health Care	30/10/23
Reviva Shares Surge After Late-Stage Schizophrenia Trial Meets Primary Endpoint	30/10/23
Top Midday Gainers	30/10/23
Reviva Pharmaceuticals Says Phase 3 RECOVER Trial of Brilaroxazine in Adults With Schizophrenia Meets Primary Endpoint	30/10/23
Reviva Pharma's schizophrenia drug succeeds in late-stage study	30/10/23
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	30/10/23
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday	25/09/23
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Completion for Pivotal Phase 3 Recover Study for Brilaroxazine in Schizophrenia	17/08/23
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Other languages

Filters